PACB NASDAQ
Pacific Biosciences of California, Inc.
1W: +25.0%
1M: +43.3%
3M: +75.0%
YTD: +33.1%
1Y: +21.3%
3Y: -66.8%
5Y: -90.3%
$2.45
+0.20 (+8.89%)
Weekly Expected Move ±21.8%
$1
$2
$2
$3
$3
Credit Risk of going bust: higher than 91% of companies Debt: 48.1% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the riskiest tenth, about 1 in 20 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.29 (down 88%), Pacific Biosciences of California, Inc. would be worth roughly what it owes.
Total debt $706.1M against a stock market value of $761.5M.
Distance to default 1.52 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $322.2M (short-term plus half of long-term), stock volatility 92.2%; Altman Z -4.46. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.29 (down 88%), Pacific Biosciences of California, Inc. would be worth roughly what it owes.
Total debt $706.1M against a stock market value of $761.5M.
Distance to default 1.52 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $322.2M (short-term plus half of long-term), stock volatility 92.2%; Altman Z -4.46. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
1 neutral
0 bearish
Articles (24h)
1
Hourly Sentiment (24h)
-0.45
Bearish
0 bullish
1 neutral
1 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (100)
Here's Why You Should Hold PacBio Stock in Your Portfolio for Now
Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors
Pacific Biosciences of California (PACB) Declines More Than Market: Some Information for Investors
PacBio Teams With TychoBio to Advance AI-Driven RNA Therapeutics
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap Down – Here’s Why
Insider Selling: Pacific Biosciences of California (NASDAQ:PACB) Insider Sells $2,058,244.65 in Stock
Why Pacific Biosciences of California (PACB) Dipped More Than Broader Market Today
PacBio and TychoBio Collaborate to Train AI Models for Rare Disease RNA Therapeutics
Market Movers | Winners: PTC, PCVX, RXO | Losers: SPHR, CAPR, CHRW - Trefis
Why PacBio (PACB) Stock Is Trading Up Today
Why PacBio (PACB) Stock Is Trading Up Today - StockStory
PACB Oct 2026 1.500 call (PACB261016C00001500) interactive stock chart - Yahoo Finance UK
Pacific Biosciences of California (PACB) Rises Higher Than Market: Key Facts
Pacific Biosciences of California (PACB) Rises Higher Than Market: Key Facts
Pacific Biosciences of California (PACB) Rises Higher Than Market: Key Facts - Yahoo Finance
Catalyst Watch: Microsoft event, FOMC talk, and the finish line for Paramount-Warner Bros.
PACB Stock Climbs As Traders Eye Conference Catalyst - StocksToTrade
3 Biotech Stocks Put Traders Are Targeting Today
Pacific Biosciences: Stock Surges As New Use Case Seen - But Caution Is Warranted (PACB) - Seeking Alpha
Pacific Biosciences of California (NASDAQ:PACB) Stock Sees Heavy Call Option Buying
Why Is PacBio (PACB) Stock Soaring Today
Pacific Biosciences of California (NASDAQ:PACB) Shares Climb 6.1% – Still a Buy?
PACB Stock Grinds Higher As Traders Eye Morgan Stanley Chat - StocksToTrade
PACB Stock Grinds Higher As Traders Eye Morgan Stanley Chat - timothysykes.com
Stocks making big moves yesterday: TTM Technologies, PacBio, Nvidia, Palo Alto Networks, and Teleflex
Why PacBio (PACB) Stock Is Trading Up Today - StockStory
Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know
Pacific Biosciences of California (PACB) Beats Stock Market Upswing: What Investors Need to Know
3 Unprofitable Stocks That Fall Short
1 Stock Under $10 with Exciting Potential and 2 We Avoid
2 Small-Cap Stocks for Long-Term Investors and 1 Facing Headwinds
Pacific Biosciences Targets Clinical Growth, $40M Savings With HiFi Sequencing Push
Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today
Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today
Why Pacific Biosciences of California (PACB) Outpaced the Stock Market Today - Yahoo Finance
3 Cash-Burning Stocks We Approach with Caution
Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know
Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know
Q2 Earnings Highlights: PacBio (NASDAQ:PACB) Vs The Rest Of The Life Sciences Tools & Services Stocks
Pacific Biosciences (PACB) Up 11.6% Since Last Earnings Report: Can It Continue?
Pacific Biosciences (PACB) Up 11.6% Since Last Earnings Report: Can It Continue?
PacBio to Participate in the Morgan Stanley 24ᵗʰ Annual Global Healthcare Conference
10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead?
PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test
PACB Cuts 2026 Outlook as Clinical Adoption Faces Its Crucial Test
$PACB stock is up 17% today. Here's what we see in our data. - Quiver Quantitative
PacBio Q2 Earnings Meet Estimates, Revenues Miss, 2026 Sales View Cut
PacBio forecasts $155M-$165M 2026 revenue while shifting to a leaner structure and pushing SPRQ-Nx adoption
Pacific Biosciences of California (PACB) Reports Q2 Loss, Lags Revenue Estimates
Pacific Biosciences of California Non-GAAP EPS of -$0.14 misses by $0.01, revenue of $39M misses by $1.58M
What's in Store for These 4 Healthcare Companies This Earnings Season?
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives $1.83 Consensus PT from Brokerages
Beta Bionics, Inc. (BBNX) Reports Q2 Loss, Tops Revenue Estimates
Pacific Biosciences of California (PACB) Laps the Stock Market: Here's Why
Pacific Biosciences of California (PACB) Laps the Stock Market: Here's Why - Yahoo Finance
Amova Asset Management Americas Inc. Has $9.22 Million Stock Position in Pacific Biosciences of California, Inc. $PACB
Here's Why Pacific Biosciences of California (PACB) Fell More Than Broader Market
Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know
Resmed Divests MatrixCare Business to Sharpen Focus on Connected Care
NTRA's Signatera Gains EU IVDR Certification for Multiple Cancers
Here's Why You Should Add Merit Medical Stock to Your Portfolio Now
WST Completes SmartDose Sale to AbbVie to Focus on Core Growth
Here's Why You Should Add PacBio Stock to Your Portfolio Now
CareDx Completes Naveris Acquisition and Expands Oncology Reach
Here's Why You Should Retain AMN Stock in Your Portfolio for Now
Pacific Biosciences of California (PACB) Stock Drops Despite Market Gains: Important Facts to Note
Pacific Biosciences of California (PACB) Stock Drops Despite Market Gains: Important Facts to Note - Yahoo Finance
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's Why
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
PacBio (PACB) Stock Faces Mixed Analyst Target Changes After Valuation Revisions - Yahoo Finance
Is Pacific Biosciences of California, Inc. (PACB) One of the Best Genomics Stocks to Buy According to Wall Street?
Is Pacific Biosciences of California, Inc. (PACB) One of the Best Genomics Stocks to Buy According to Wall Street?
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's Why
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: Here's Why - Yahoo Finance
Cathie Wood Sells Robinhood Stock, Doubles Down On This George Soros-Backed AI Stock
Here's Why You Should Retain Glaukos Stock in Your Portfolio Now
Here's Why You Should Add PacBio Stock to Your Portfolio Now
3 Promising Genomics & Synthetic Biology Stocks in Spotlight in 2026
PacBio Expands HiFi Sequencing Reach With New SPRQ-Nx Technology
Here's Why You Should Retain CONMED Stock in Your Portfolio Now
Here's Why You Should Hold Avantor Stock in Your Portfolio for Now
Reasons to Retain TransMedics Stock in Your Portfolio for Now
Can MDT Stock Gain From Its Planned Acquisition of SPR Therapeutics?
Here's Why You Should Retain McKesson Stock in Your Portfolio for Now
MMED's Latest Study Supports the Strength of 780G SmartGuard Algorithm
QIAGEN Stock Up on the Launch of AI-Powered Workflow Agent Platform
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
Reasons to Add West Pharmaceutical Stock to Your Portfolio Now
Here's Why You Should Add Cardinal Health Stock to Your Portfolio Now
PACB & Blank Bio Partner to Advance RNA Foundation Models in Oncology
[10-Q] PACIFIC BIOSCIENCES OF CALIFORNIA, INC. Quarterly Earnings Report - Stock Titan
PacBio tumbles after narrowing full-year revenue guidance
PACB Q1 Earnings Beat, Revenues Miss Estimates, Gross Margin Down
PacBio (PACB) Q1 2026 Earnings Call Transcript
PacBio expects $165M-$175M 2026 revenue as SPRQ-Nx ships later this month
Pacific Biosciences of California (PACB) Reports Q1 Loss, Lags Revenue Estimates
Here are the major earnings after the close Thursday
PacBio Pre-Q1 Analysis: Time to Buy, Hold or Sell the Stock Now?
OrthoPediatrics (KIDS) Reports Q1 Loss, Beats Revenue Estimates
Pacific Biosciences of California (PACB) Dips More Than Broader Market: What You Should Know